Efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in patients with secondary liver cancer: a preliminary result from CTILC study

Xia Wu, Shihong Ying, Jing Huang, Changsheng Shi, Jiansong Ji, Zhiyi Peng, Guanhui Zhou, Zhichao Sun, Junhui Sun, Wenqiang Yu, Wenhao Hu, Xin Zhang, Jian Zhou, Guoliang Shao, Zhihai Yu, Qinming Hou, Wenjiang Gu, Tiefeng Li, Xiaoxi Xie, Guohong Cao, Haijun Du, Dedong Zhu, Huanhai Xu, Jun Han, Wenbin Ji, Jian Fang, Ling Li, Jiaping Zheng, Jun Luo, Yutang Chen, Tingyang Hu, Hongjie Hu, Xiaohua Guo


Background: This study aimed to assess the treatment response, short-term overall survival (OS) and safety profiles of drug-eluting beads transarterial chemoembolization (DEB-TACE) in patients with secondary liver cancer.
Methods: Fifty-five patients with secondary liver cancer underwent DEB-TACE were enrolled in this prospective cohort study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST). OS was calculated from the time of DEB-TACE operation until the date of death.
Results: The complete response (CR) and objective response rate (ORR) at 1–3 months post DEB-TACE were 12.7% and 67.3 %. Mean OS was 383 d (95% CI: 360–406), and 6-month OS rate was 93.4%±3.7%. Subgroup analysis revealed previous conventional TACE (cTACE) treatment was correlated with worse ORR (P=0.028), and it was a risk factor for ORR achievement (P=0.021). As for liver function, the percentages of abnormal TP (P=0.031), TBIL (P=0.022), ALT (P=0.002) and AST (P=0.035) were increased at 1 week post DEB-TACE compared to baseline, while these four indexes returned to baseline (all P>0.05) at 1–3 months post DEB-TACE. As to safety profiles, 41 (66.1%), 28 (45.2%), 17 (27.4%), 8 (12.9%) and 6 (9.7%) cases had pain, vomiting, fever, nausea and other adverse events (AEs) respectively during DEB-TACE operation, while 26 (41.9%), 9 (14.5%), 8 (12.9%), 4 (6.5%), 1 (1.6%) and 2 (3.2%) cases had pain, fever, vomiting, nausea, bone marrow toxicity and other AEs respectively at 1 month after DEB-TACE operation.
Conclusions: DEB-TACE was efficient and well tolerated in treating patients with secondary liver cancer.